Balaxi Pharmaceuticals Limited

April 03, 2023

To,
Listing Department,
National Stock Exchange of India Limited
Exchange Plaza, Plot No C-1, Block G, Bandra Kurla Complex,
Bandra (E), Mumbai – 400051

NSE Symbol: BALAXI

<u>Subject: Declaration under Regulation 31(4) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011</u>

Dear Sir/Madam,

Please find enclosed declaration by the Promoters of the Company under Regulation 31(4) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for the financial year ended March 31, 2023.

This is for your information and records.

Yours Faithfully,

For Balaxi Pharmaceuticals Limited

Udayan Shukla

(Company Secretary & Compliance Officer) Membership No.: F11744

Encl: As above

Phone: +91 40 23555300 | Email: info@balaxi.in | Website: www.balaxipharma.in



Date: April 03, 2023

To, Listing Department National Stock Exchange of India Limited Exchange Plaza, C-1 Block G, Bandra Kurla Complex, Bandra (E), Mumbai-400051

The Chairman
Audit Committee
Balaxi Pharmaceuticals Limited
Plot no.409, H. No. 8-2-293, Maps
Towers, 3rd Floor, Phase-III, Road No.
81, Jubilee Hills

NSE Symbol: BALAXI

<u>Subject: Declaration under Regulation 31(4) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011</u>

Dear Sir/Madam,

I, Ashish Maheshwari, Director of Balaxi Overseas Private Limited, Promoter of Balaxi Pharmaceuticals Limited ("the Company") hereby declare that the Promoter and the Promoter Group along with persons acting in concert of the Company, have not made any encumbrance, directly or indirectly, during the financial year ended March 31, 2023.

You are requested to take the same on record.

For and on Behalf of Promoters and Promoters Group,

For Balaxi Overseas Private Limited

Ashish Maheshwari

(Director)

DIN: 01575984